免疫检查点活性蛋白及相关产品 CTLA-4,PD-1,IDO1,B7-H4,LAG-3,Tim-3

来源：作者：人气：-发表时间：2023-11-15 09:04:00【大中小】

免疫检查点活性蛋白及相关产品

CTLA-4,PD-1,IDO1,B7-H4,LAG-3,Tim-3

◆活性免疫检测点蛋白

B7-H4 (human):Fc (human) (rec.)	CHI-HF-210B7H4
B7-H4 (mouse):Fc (mouse) (rec.)	CHI-MF-110B7H4
CTLA-4 (human):Fc (human) (rec.)	CHI-HF-210A4
CTLA-4 (human):Fc (human) (rec.) (non-lytic)	CHI-HF-220A4
CTLA-4 (human):Fc (mouse) (rec.)	CHI-HF-211A4
CTLA-4 (mouse):Fc (mouse) (rec.)	CHI-MF-110A4
CTLA-4 (mouse):Fc (mouse) (rec.) (non-lytic)	CHI-MF-120A4
PD-1 (human):Fc (human) (rec.)	CHI-HF-210PD1
PD-1 (human):Fc (human) (rec.) (non-lytic)	CHI-HF-220PD1
PD-1 (mouse):Fc (mouse) (rec.)	CHI-MF-110PD1
PD-L1/B7-H1 (human):Fc (human) (rec.)	CHI-HF-210PDL1
PD-L1/B7-H1 (human):Fc (human) (rec.) (non-lytic)	CHI-HF-220PDL1
PD-L1/B7-H1 (mouse):Fc (mouse) (rec.)	CHI-MF-110PDL1
PD-L1/B7-H1 (mouse):Fc (mouse) (rec.) (non-lytic)	CHI-MF-120PDL1
PD-L2 (human):Fc (human) (rec.)	CHI-HF-210PDL2
PD-L2 (human):Fc (human) (rec.) (non-lytic)	CHI-HF-220PDL2
PD-L2 (mouse):Fc (mouse) (rec.)	CHI-MF-110PDL2

◆IDO1酶&主要抑制剂

IDO1 (human) Enzyme+Inhibitor Set	AG-44B-0006
IDO1 (human) (rec.) (His) (highly active)	AG-40B-0161

MMG-0358 Potent Triazole IDO1 Inhibitor AG-CR1-3630

IC50值，mIDO1细胞检测是2 nM，hIDO1细胞检测是80 nM，hIDO1（pH 6.5）酶活检测是330 nM，hIDO1（pH7.4）的酶活检测是71 nM。体内有活性。

参考文献

Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition: U.F. Roehrig, et al.; J. Med. Chem. , 55, 5270 (2012)

◆肿瘤免疫治疗的LAG-3

功能性封闭抗体
LAG-3 (human), mAb (blocking) (17B4)	AG-20B-0012
LAG-3 (human), mAb (blocking) (17B4) (preservative free)	AG-20B-0012PF
LAG-3, mAb (blocking) (11E3)	AG-20B-0011
LAG-3, mAb (blocking) (11E3) (preservative free)	AG-20B-0011PF
生物活性蛋白
LAG-3 (human):Fc (human) (rec.)	AG-40B-0031
LAG-3 (mouse):Fc (mouse) (rec.)	AG-40B-0039

◆T-细胞免疫球蛋白和粘蛋白结构域

Tim-3 (human):Fc (human) (rec.)	CHI-HF-210T3
Tim-3 (mouse):Fc (mouse) (rec.)	CHI-MF-110T3

◆CD1d配体抗肿瘤佐剂

α-Galactosylceramide

Potent NKT Cell stimulator

强有效NKT 激活剂

AG-CN2-0013

在人类和小鼠NKT细胞里MHC-I蛋白和CD1d分子脂质结合的特异性配体。

参考文献

LIT: Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine: F. Gableh, et al.; J. Biomed. Sci., 23, 16 (2016)

※ 本页面产品仅供研究用，研究以外不可使用。